David Rosenbaum, MD
Cardiovascular Disease · Colorado Springs, CONPI 1346284601
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $676 of the $925 with a category attached, or 73.1%. Medtronic accounts for 83.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $776 and has fallen 96.8% since, to $25 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in CO, where the typical reported total is $1,537.
Across 7 payments — averaging $132.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$776
- Abiomed$102
- Dexcom, Inc.$25
- Boston Scientific$22
Across 1 payment — averaging $5146.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$5K
What the payments were for
- Travel & lodging$67673%
- Food & beverage$24927%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $776 |
| Abiomed | 1 | $102 |
| Dexcom, Inc. | 1 | $25 |
| Boston Scientific | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mosaic$535
- CoreValve Evolut$241
- Impella$102
How this compares
$925 in reported general payments places this provider in the 40th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 442 | $608,373 |
| VyndamaxTafamidis | 12 | $304,434 |
| Repatha SureclickEvolocumab | 131 | $165,146 |
| EntrestoSacubitril/Valsartan | 54 | $98,961 |
| XareltoRivaroxaban | 52 | $60,065 |
| JardianceEmpagliflozin | 35 | $48,523 |
| Praluent PenAlirocumab | 31 | $42,340 |
| MultaqDronedarone Hcl | 14 | $24,461 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 33 | $13,536 |
| PradaxaDabigatran Etexilate Mesylate | 31 | $9,791 |
| Valsartan | 261 | $8,679 |
| Rosuvastatin Calcium | 711 | $7,965 |
| Flecainide Acetate | 95 | $7,161 |
| Metoprolol Succinate | 414 | $5,532 |
| Atorvastatin Calcium | 511 | $5,117 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Colorado Springs
- Deborah JalowiecColorado Springs$106K
- Preetham ReddyColorado Springs$9K
- James MillerColorado Springs$6K
- Kimberly DulaneyColorado Springs$6K
- Brian MetzColorado Springs$6K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.